Description
The H1N1 flu epidemic created a public health emergency in 2009. It also created an opportunity for vaccine manufacturers to demonstrate that working with governments of the US and countries around the world, they could manufacture and distribute a vaccine for the virus strain that may have had an impact in reducing cases and deaths.
Who were the companies that performed best in this market? How did goverment contracts play out? Most importantly, what are lessons for future pandemic and high publicity vaccine products? Kalorama has looked at vaccine products over the past decade and has seen the rise of interest in these products among pharmaceutical companies. While many suggest the H1N1 was a one time event, Kalorama believes there is something important to be gained in a market review of 2009 flu vaccine sales that will inform executives, investors and market watchers who are interested in the vaccine market.
This Kalorama Information report takes a detailed look at the H1N1 vaccine sales of 2009 based on available annual reports. Companies covered include AstraZeneca, Novartis, Glaxo and CSL among others. As part of its coverage, the report includes:
- 2009 H1N1 Vaccine Sales Results
- Stockpiles, Returns, Delivery Systems and other Issues and Trends in Vaccine Sales
- H1N1 Etiology and Statistics
- Forecasts for 2010-2013 Influenza Vaccine Market
- Trending in Government Contracts
- Seasonal and H1N1 Flu Market Interplay
- Conclusions for Future Pandemic Vaccine Sales
- Market Share of Major Companies
- Company Profiles
As part of its coverage, the following vaccine makers are profiled
- Baxter Healthcare
- GlaxoSmithKline
- CSL
- Medimmune (Astra Zeneca)
- Merck & Co. Inc
- Novartis
- Sanofi Pasteur
- Sinovac
- Hualan Biological Engineering Co.
- Novovax
This Kalorama Information report was created as the result of both secondary and primary research. Research was conducted into the annual reports of major vaccine concerns, trade media coverage, company websites and medical and government literature. Interviews were used to make forecasts on the vaccine market and the influenza vaccine market for 2010-2014, which have been utilized in our estimate of the swine flu vaccine market impact for the 2010-2014 years. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources.
